• Consensus Rating: Buy
  • Consensus Price Target: $20.67
  • Forecasted Upside: 138.10 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$8.68
▼ -0.26 (-2.91%)

This chart shows the closing price for EXAI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Exscientia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EXAI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EXAI

Analyst Price Target is $20.67
▲ +138.10% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Exscientia in the last 3 months. The average price target is $20.67, with a high forecast of $27.00 and a low forecast of $15.00. The average price target represents a 138.10% upside from the last price of $8.68.

This chart shows the closing price for EXAI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Exscientia.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/9/2022Morgan StanleyLower TargetEqual Weight$18.00 ➝ $15.00Low
8/24/2022Morgan StanleyLower TargetEqual Weight$20.00 ➝ $18.00Low
6/13/2022Morgan StanleyLower TargetEqual Weight$21.00 ➝ $20.00High
5/24/2022The Goldman Sachs GroupLower TargetBuy$23.00 ➝ $20.00Low
4/11/2022Morgan StanleyBoost TargetEqual Weight$20.00 ➝ $21.00High
10/26/2021Bank of AmericaInitiated CoverageBuy$27.00High
10/26/2021Morgan StanleyInitiated CoverageEqual Weight$25.00High
10/26/2021The Goldman Sachs GroupInitiated CoverageBuy$30.00High
(Data available from 10/5/2017 forward)

News Sentiment Rating

0.48 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/9/2022
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/8/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
5/8/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
6/7/2022
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2022
  • 3 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
9/5/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
10/5/2022

Current Sentiment

  • 3 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Exscientia logo
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Read More

Today's Range

Now: $8.68
Low: $8.35
High: $8.71

50 Day Range

MA: $9.72
Low: $7.27
High: $12.92

52 Week Range

Now: $8.68
Low: $6.56
High: $26.18

Volume

1,059 shs

Average Volume

122,928 shs

Market Capitalization

$1.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Exscientia?

The following Wall Street research analysts have issued research reports on Exscientia in the last twelve months: Bank of America Co., Morgan Stanley, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for EXAI.

What is the current price target for Exscientia?

3 Wall Street analysts have set twelve-month price targets for Exscientia in the last year. Their average twelve-month price target is $20.67, suggesting a possible upside of 138.1%. Bank of America Co. has the highest price target set, predicting EXAI will reach $27.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $15.00 for Exscientia in the next year.
View the latest price targets for EXAI.

What is the current consensus analyst rating for Exscientia?

Exscientia currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EXAI will outperform the market and that investors should add to their positions of Exscientia.
View the latest ratings for EXAI.

What other companies compete with Exscientia?

How do I contact Exscientia's investor relations team?

The company's listed phone number is 44-0-18-6581-8941 and its investor relations email address is [email protected] The official website for Exscientia is www.exscientia.ai. Learn More about contacing Exscientia investor relations.